Navigation Links
KLRI Receives Grant From NIH to Study Stress Resilience in Older Adults
Date:8/6/2008
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Caliper Life Sciences' Fourth Quarter 2008 Financial Results Conference Call Notice 2Health News:PNAS announces 2008 Cozzarelli Prize recipients 2Health News:NBA and WNBA Help Teens Take Their Best Shot at Health With New Vaccines for Teens Educational Campaign 2Health News:NBA and WNBA Help Teens Take Their Best Shot at Health With New Vaccines for Teens Educational Campaign 3Health News:NBA and WNBA Help Teens Take Their Best Shot at Health With New Vaccines for Teens Educational Campaign 4Health News:NBA and WNBA Help Teens Take Their Best Shot at Health With New Vaccines for Teens Educational Campaign 5Health News:SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents 2Health News:SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents 3Health News:SYNTAX defines borders between CABG and PCI with TAXUS drug-eluting stents 4Health News:FAAN Awards Community Outreach Grants 2Health News:FAAN Awards Community Outreach Grants 3Health News:Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes 2Health News:Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes 3Health News:Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes 4
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Its Better to Give Than to Receive 55771 1Its Better to Give Than to Receive 55771 2Its Better to Give Than to Receive 55771 3Change in Seasons 3A Ideal Time to Review Healthy Aging Habits 55768 1Change in Seasons 3A Ideal Time to Review Healthy Aging Habits 55768 2Prostate Cancer Over Diagnosed 3A Study 55767 1Prostate Cancer Over Diagnosed 3A Study 55767 2Prostate Cancer Over Diagnosed 3A Study 55767 3